159 related articles for article (PubMed ID: 35621092)
1. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M; Anguita Sánchez M; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Esteve-Pastor MA; Freixa-Pamias R; Lekuona I; Pérez-Cabeza AI; Ureña I; Vázquez Rodríguez JM; Rafols Priu C; Marin F
Cardiol J; 2022; 29(4):601-609. PubMed ID: 35621092
[TBL] [Abstract][Full Text] [Related]
2. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
Anguita Sánchez M; Marín F; Masjuan J; Cosín-Sales J; Vázquez Rodríguez JM; Barrios V; Barón-Esquivias G; Lekuona I; Pérez-Cabeza AI; Freixa-Pamias R; Parra Jimenez FJ; Monzer Khanji Khatib M; Rafols Priu C; Sanmartín Fernández M
Cardiol J; 2022; 29(6):936-947. PubMed ID: 36200548
[TBL] [Abstract][Full Text] [Related]
3. Validating the predictive ability of the 2MACE score for major adverse cardiovascular events in patients with atrial fibrillation: results from phase II/III of the GLORIA-AF registry.
Ding WY; Fawzy AM; Romiti GF; Proietti M; Pastori D; Huisman MV; Lip GYH;
J Thromb Thrombolysis; 2024 Jan; 57(1):39-49. PubMed ID: 37566295
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
Pastori D; Farcomeni A; Poli D; Antonucci E; Angelico F; Del Ben M; Cangemi R; Tanzilli G; Lip GY; Pignatelli P; Violi F
Intern Emerg Med; 2016 Mar; 11(2):199-204. PubMed ID: 26471883
[TBL] [Abstract][Full Text] [Related]
5. Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry.
Esteve-Pastor MA; Rivera-Caravaca JM; Roldán V; Sanmartin Fernández M; Arribas F; Masjuan J; Barrios V; Cosin-Sales J; Freixa-Pamias R; Recalde E; Pérez-Cabeza AI; Manuel Vázquez Rodríguez J; Ràfols Priu C; Anguita Sánchez M; Lip GYH; Marin F
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):38-46. PubMed ID: 36318457
[TBL] [Abstract][Full Text] [Related]
6. Adverse cardiovascular outcomes in atrial fibrillation: Validation of the new 2MACE risk score.
Polovina M; Đikić D; Vlajković A; Vilotijević M; Milinković I; Ašanin M; Ostojić M; Coats AJS; Seferović PM
Int J Cardiol; 2017 Dec; 249():191-197. PubMed ID: 28986061
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation.
Rivera-Caravaca JM; Marín F; Esteve-Pastor MA; Raña-Míguez P; Anguita M; Muñiz J; Cequier Á; Bertomeu-Martínez V; Valdés M; Vicente V; Lip GYH; Roldán V
Am J Cardiol; 2017 Dec; 120(12):2176-2181. PubMed ID: 29111209
[TBL] [Abstract][Full Text] [Related]
8. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
Rivera-Caravaca JM; Anguita Sanchez M; Sanmartín Fernández M; Rafols C; Barón-Esquivias G; Arribas Ynsaurriaga F; Freixa-Pamias R; Lekuona Goya I; Vázquez Rodríguez JM; Pérez-Cabeza AI; Cosín-Sales J; Ureña Montilla I; Álvarez-Vieitez Blanco A; Marín F
Am J Cardiol; 2023 Sep; 203():122-127. PubMed ID: 37487406
[TBL] [Abstract][Full Text] [Related]
9. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
[TBL] [Abstract][Full Text] [Related]
10. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
12. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.
Marin F; Fernández MS; Lekuona I; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Freixa-Pamias R; Masjuan J; Pérez-Cabeza AI; Schilling VR; Vázquez Rodríguez JM; Priu CR; Sánchez MA
J Comp Eff Res; 2022 Nov; 11(16):1173-1184. PubMed ID: 36148923
[No Abstract] [Full Text] [Related]
14. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients.
Pastori D; Rivera-Caravaca JM; Esteve-Pastor MA; Roldán V; Marín F; Pignatelli P; Violi F; Lip GYH
Circ J; 2018 Apr; 82(5):1286-1292. PubMed ID: 29553090
[TBL] [Abstract][Full Text] [Related]
16. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
17. Global Prospective Safety Analysis of Rivaroxaban.
Kirchhof P; Radaideh G; Kim YH; Lanas F; Haas S; Amarenco P; Turpie AGG; Bach M; Lambelet M; Hess S; Camm AJ;
J Am Coll Cardiol; 2018 Jul; 72(2):141-153. PubMed ID: 29976287
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban.
Manito N; Cepeda-Rodrigo JM; Farré N; Castillo Orive M; Galve E; Jiménez-Candil J; García-Pinilla JM; López Sánchez ES; Rafols C; Gómez Doblas JJ
Clin Cardiol; 2024 Feb; 47(2):e24189. PubMed ID: 38018889
[TBL] [Abstract][Full Text] [Related]
19. Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis.
Sakuma I; Uchiyama S; Atarashi H; Inoue H; Kitazono T; Yamashita T; Shimizu W; Ikeda T; Kamouchi M; Kaikita K; Fukuda K; Origasa H; Shimokawa H
Heart Vessels; 2019 Nov; 34(11):1839-1851. PubMed ID: 31127325
[TBL] [Abstract][Full Text] [Related]
20. Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation.
Rivera-Caravaca JM; Teruel-Montoya R; Roldán V; Cifuentes-Riquelme R; Crespo-Matas JA; de Los Reyes-García AM; Águila S; Fernández-Pérez MP; Reguilón-Gallego L; Zapata-Martínez L; García-Barberá N; Vicente V; Marín F; Martínez C; González-Conejero R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33198388
[No Abstract] [Full Text] [Related]
[Next] [New Search]